Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

0.1424
-0.0173-10.83%
Post-market: 0.14760.0052+3.65%19:49 EDT
Volume:13.23M
Turnover:1.90M
Market Cap:69.63M
PE:-0.22
High:0.1567
Open:0.1527
Low:0.1402
Close:0.1597
52wk High:3.87
52wk Low:0.1138
Shares:489.00M
Float Shares:306.00M
Volume Ratio:1.32
T/O Rate:4.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6496
EPS(LYR):-0.7455
ROE:-783.37%
ROA:-62.39%
PB:-0.74
PE(LYR):-0.19

Loading ...

Analysts Conflicted on These Healthcare Names: Gossamer Bio (GOSS) and Biogen (BIIB)

TIPRANKS
·
Apr 02

Gossamer Bio Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
Mar 23

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Mar 23

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Mar 21

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)

TIPRANKS
·
Mar 19

Levi & Korsinsky probes Gossamer Bio statements after PROSERA Phase 3 trial miss

Reuters
·
Mar 19

Gossamer Bio’s Seralutinib Future in Doubt After PROSERA Miss in PAH Raises FDA, Funding and Viability Risks

TIPRANKS
·
Mar 19

Portnoy Law Firm probes possible securities fraud at Gossamer Bio after 80.14% stock plunge

Reuters
·
Mar 18

Top News Today/Canada: Lululemon Appoints New Board Member; Fourth-Quarter Sales Rise

Dow Jones
·
Mar 18

CORRECTED-Gossamer Bio Q4 net loss widens

Reuters
·
Mar 18

Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million

Reuters
·
Mar 18

BRIEF-Gossamer Bio Q4 EPS USD -0.21

Reuters
·
Mar 18

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Mar 18

Gossamer Bio: Pauses Enrollment in Phase 3 Seranata Study in Ph-Ild While Co Evaluates Implications of Prosera Results

THOMSON REUTERS
·
Mar 18

Gossamer Bio: Co Implemented Reduction in Force to Align Resources With Near-Term Priorities

THOMSON REUTERS
·
Mar 18